235 East 42nd Street
About Pfizer, Inc.
At Pfizer Worldwide Research & Development (WRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing critical medicines and treatments for patients around the world.
Pfizer’s OWNIT! Culture
Through Pfizer’s shared mission to impact global health, Pfizer has built a unique OWNIT! culture to empower you to play your part in each of Pfizer’s life-changing achievements. So what does OWNIT! mean? It means taking ownership of your career and the contribution you make to the business and the patients and customers impacted by Pfizer’s business. This encouragement for personal progress allows colleagues to treat each other with honesty and respect, to act quickly and decisively, all to deliver results with commitment and care.
Professional Development at Pfizer
Pfizer’s belief that every person matters is also what proves their commitment to you. Whatever your talent or skill, you will be taught how to become an expert in your field through tools like Pfizer’s Mentor Match online tool and creating detailed career “roadmaps” with your manager that take into account your interests and aspirations as well as Pfizer’s business needs. Managers are also encouraged to provide frequent performance feedback instead of relying solely on yearly evaluations. From here, you’ll be inspired to refine – and redefine – your personal and professional goals.
Diversity at Pfizer
Pfizer believes that diversity is just as crucial to building a successful business as it is to building a vibrant culture. Pfizer’s community is one of the greatest building aspects about their culture. And their Diversity and Inclusion team ensures that every colleague experiences a fair and supportive environment. From holding managers and leaders accountable for creating inclusive and equitable workplaces, to helping colleagues appreciate the value of diversity, Pfizer is a place where people from all backgrounds and abilities can build a fulfilling career and reach their full potential.
Finding Your Community and Making a Difference
With more than 95 Colleague Resource Groups (CRGs) located around the world, working at Pfizer means finding a community. Pfizer offers CRGs focused on the following groups: Asians, Blacks, colleagues with disabilities, Latinos, LGBTQ, Veterans and Women. These CRGs offer support, mentoring and networking opportunities to help members enhance their skills and advance their careers. They also help their communities by participating in volunteer and philanthropic activities, from sponsoring student scholarships to health fairs focused on the unique healthcare concerns of diverse populations.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of today. As one of the world’s premier pharmaceuticals companies, Pfizer’s network and influence spans the entire globe. But in every country and continent, Pfizer colleagues are energized by a unique spirit. No matter the role or responsibility, colleagues are empowered by the belief that the work they do has a direct impact on patients.
3979 articles with Pfizer, Inc.
2/1/2019Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.
For 2018, Pfizer reported revenues of $53.6 billion, which was 2 percent operational growth. The fourth quarter brought in $14 billion, which was 5 percent operational growth.
Full-Year 2018 Revenues of $53.6 Billion, Reflecting 2% Operational Growth; Fourth-Quarter 2018 Revenues of $14.0 Billion, Reflecting 5% Operational Growth
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.
1/29/2019Pfizer and Eli Lilly and Co. announced that their tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis (OA) pain in a Phase III trial.
Pfizer is a big company with a diverse portfolio, but it hasn’t really been noted for its presence in the oncology market. But now, Pfizer offers 17 drugs to treat cancer, with four approved in the U.S. in 2017.
It’s no secret that the pharmaceutical industry spends a significant amount of money lobbying state and federal governments to gain leverage that will benefit individual companies and the industry overall.
Although that is good news, cancer is the second-most common cause of death in the U.S., with more than 1.7 million new cancer cases each year and more than 600,000 cancer deaths. The report notes that one of the biggest factors in decreased cancer rates are lower tobacco smoking rates.
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
After conducting a routine research-and-development review, Pfizer is easing away from preclinical biosimilar development. The bottom line is the company is ending five preclinical programs in its biosimilar area and cutting 150 positions.
US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM
Ahead of the JP Morgan Healthcare Conference, Jamie Dimon, chief executive officer of JP Morgan Chase, hosted a private dinner for biopharma executives Sunday night. Although the dinner was private, apparently one of the hot topics of discussion was a company not represented at the party—Amazon.
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery
CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments.
In 2013 Pfizer launched its Dare to Try initiative, a project designed to foster internal innovation at the pharma giant. It was an effort that encouraged employees to not be afraid to fail as they reached for the sky.
Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
Oral JAK3 inhibitor trial initiated for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Pharmaceutical companies traditionally adjust the price of drugs twice a year, so it wouldn’t normally be a hot topic. But drug prices have been a controversial subject for several years, especially in politics.
PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference on January 7, 2019
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 a.m. Pacific Standard Time.